This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Aralez Pharmaceuticals Inc.
Drug Names(s): Lansoprazole/Naproxen
Description: POZEN is developing a suite of proprietary product candidates, designated as its PN products platform, that combine an acid inhibitor, e.g., a proton pump inhibitor (PPI), with a non-steroidal anti-inflammatory drug (NSAID) in a single tablet. The products are intended to provide effective management of pain and inflammation with fewer gastrointestinal side effects and complications compared to an NSAID taken alone.
PN 100 combines the PPI Lansoprazole with the NSAID Naproxen. Lansoprazole, like other proton-pump inhibitors, blocks the enzyme in the wall of the stomach that produces acid. By blocking the enzyme, the production of acid is decreased, and this allows the stomach and esophagus to heal. Naproxen belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). Naproxen blocks the enzyme that makes prostaglandins (cyclooxygenase ), resulting in lower concentrations of prostaglandins. As a consequence, inflammation, pain and fever are reduced.
PN 100 News
Additional information available to subscribers only: